AE Wealth Management LLC Increases Stock Holdings in Medtronic PLC $MDT

AE Wealth Management LLC boosted its stake in Medtronic PLC (NYSE:MDT) by 17.1% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,420 shares of the medical technology company’s stock after acquiring an additional 1,521 shares during the quarter. AE Wealth Management LLC’s holdings in Medtronic were worth $908,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Brighton Jones LLC boosted its stake in shares of Medtronic by 1,368.0% in the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after purchasing an additional 37,265 shares during the period. Edgestream Partners L.P. acquired a new position in Medtronic in the 1st quarter worth $325,000. Wealthfront Advisers LLC lifted its holdings in Medtronic by 38.7% in the 1st quarter. Wealthfront Advisers LLC now owns 86,005 shares of the medical technology company’s stock worth $7,728,000 after buying an additional 24,000 shares in the last quarter. Sage Mountain Advisors LLC purchased a new position in Medtronic in the 1st quarter valued at about $266,000. Finally, Bridgewater Advisors Inc. acquired a new stake in shares of Medtronic during the first quarter valued at about $228,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Trading Up 0.3%

NYSE:MDT opened at $96.12 on Friday. The company has a market cap of $123.29 billion, a PE ratio of 26.48, a P/E/G ratio of 2.42 and a beta of 0.77. The business’s 50 day moving average is $94.37 and its two-hundred day moving average is $90.26. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. Medtronic PLC has a 52 week low of $79.29 and a 52 week high of $99.37.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.03. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The business had revenue of $8.58 billion for the quarter, compared to analyst estimates of $8.37 billion. During the same period in the prior year, the company posted $1.23 EPS. The business’s revenue was up 7.7% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, analysts predict that Medtronic PLC will post 5.46 EPS for the current year.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total transaction of $788,045.90. Following the sale, the executive vice president directly owned 35,615 shares of the company’s stock, valued at approximately $3,261,621.70. This represents a 19.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William R. Jellison purchased 2,500 shares of the firm’s stock in a transaction dated Monday, August 25th. The stock was acquired at an average cost of $92.37 per share, with a total value of $230,925.00. Following the completion of the acquisition, the director directly owned 5,000 shares in the company, valued at approximately $461,850. This trade represents a 100.00% increase in their position. The disclosure for this purchase is available in the SEC filing. 0.26% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

MDT has been the topic of several recent analyst reports. Argus boosted their price target on Medtronic from $105.00 to $115.00 and gave the stock a “buy” rating in a research note on Tuesday, August 26th. Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a report on Wednesday, October 8th. Daiwa Capital Markets upped their target price on Medtronic from $101.00 to $104.00 and gave the company a “buy” rating in a research report on Friday, September 12th. Wells Fargo & Company upped their target price on Medtronic from $98.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, August 20th. Finally, JPMorgan Chase & Co. increased their target price on Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Medtronic presently has an average rating of “Moderate Buy” and a consensus price target of $103.06.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.